description
Powered by Eupheria Biotech
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
CCCAACATTTGATTCGTCCTCTGATGGGCATGAGTCTGGCATTACAGTGCCAAGTGAGGGAGCTAGCAACGTTACTTCATATGAAAGACCTAGAGATCCAAGACTACCAGGAGAGTGGGGCTACGCTGATTCGAGATCGATTGAAGACAGAACCATTTGAAGAAAATTCCTTCTTGGAACAATTTATGATAGAGAAACTGCCAGAGGCATGCAGCATTGGTGATGGAAAGCCCTTTGTCATGAATCTGCAGGATCTGTATATGGCAGTCACCACACAAGAGGTCCAAGTGGGACAGAAGCATCA
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Quality Level
General description
MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Ryan Robb et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(15), 4749-4760 (2019-05-18)
Activating BRAF mutations, most commonly BRAFV600E, are a major oncogenic driver of many cancers. We explored whether BRAFV600E promotes radiation resistance and whether selectively targeting BRAFV600E with a BRAF inhibitor (vemurafenib, BRAFi) sensitizes BRAFV600E thyroid cancer cells to radiotherapy. Immunoblotting
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持